Inhaled preprandial human insulin with the AERx iMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: A 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safety.

Trial Profile

Inhaled preprandial human insulin with the AERx iMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: A 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safety.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2009 Actual initiation date (Aug 2007) added as reported by ClinicalTrials.gov.
    • 24 Jun 2008 The actual end date for this trial is February 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top